CN110494423A - 乐伐替尼甲磺酸盐的新晶型及其制备方法 - Google Patents
乐伐替尼甲磺酸盐的新晶型及其制备方法 Download PDFInfo
- Publication number
- CN110494423A CN110494423A CN201880024174.8A CN201880024174A CN110494423A CN 110494423 A CN110494423 A CN 110494423A CN 201880024174 A CN201880024174 A CN 201880024174A CN 110494423 A CN110494423 A CN 110494423A
- Authority
- CN
- China
- Prior art keywords
- mesylate
- degrees
- crystal form
- lenvatinib
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 85
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 title claims abstract description 76
- 238000002360 preparation method Methods 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims abstract description 3
- 101710147108 Tyrosinase inhibitor Proteins 0.000 claims abstract description 3
- 201000002510 thyroid cancer Diseases 0.000 claims abstract description 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 47
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 45
- HWLFIUUAYLEFCT-UHFFFAOYSA-N lenvatinib mesylate Chemical compound CS(O)(=O)=O.C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 HWLFIUUAYLEFCT-UHFFFAOYSA-N 0.000 claims description 24
- 229960001429 lenvatinib mesylate Drugs 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 claims description 14
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 239000003513 alkali Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 12
- 238000005457 optimization Methods 0.000 abstract description 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 2
- 239000007787 solid Substances 0.000 description 28
- 238000002411 thermogravimetry Methods 0.000 description 8
- 238000000113 differential scanning calorimetry Methods 0.000 description 7
- 229960003784 lenvatinib Drugs 0.000 description 7
- 239000011521 glass Substances 0.000 description 5
- 229910005429 FeSSIF Inorganic materials 0.000 description 4
- 238000002441 X-ray diffraction Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000003760 magnetic stirring Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- -1 acetic acid compound Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000015799 differentiated thyroid carcinoma Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明提供了乐伐替尼甲磺酸盐的新晶型及其制备方法,含有该晶型的药物组合物,以及该晶型在制备酪氨酸酶抑制剂和治疗甲状腺癌药物制剂中的用途。本发明提供的甲磺酸盐新晶型制备成本优势明显,比现有技术具有一种或多种改进的特性,对未来该药物的优化和开发具有重要价值。
Description
PCT国内申请,说明书已公开。
Claims (7)
- PCT国内申请,权利要求书已公开。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2017102770480 | 2017-04-25 | ||
CN201710277048 | 2017-04-25 | ||
CN2017109031564 | 2017-09-29 | ||
CN201710903156 | 2017-09-29 | ||
PCT/CN2018/083861 WO2018196687A1 (zh) | 2017-04-25 | 2018-04-20 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110494423A true CN110494423A (zh) | 2019-11-22 |
CN110494423B CN110494423B (zh) | 2022-04-26 |
Family
ID=63918030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201880024174.8A Expired - Fee Related CN110494423B (zh) | 2017-04-25 | 2018-04-20 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN110494423B (zh) |
WO (1) | WO2018196687A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113533544A (zh) * | 2020-04-16 | 2021-10-22 | 先声药业有限公司 | 一种甲磺酸仑伐替尼的有关物质检测方法 |
CN114174264A (zh) * | 2020-04-24 | 2022-03-11 | 成都苑东生物制药股份有限公司 | 一种甲磺酸仑伐替尼晶型xi及其制备方法 |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110818634B (zh) * | 2018-08-13 | 2021-11-30 | 上海新礼泰药业有限公司 | 甲磺酸乐伐替尼的精制方法 |
CN111574359A (zh) * | 2019-02-19 | 2020-08-25 | 愈磐生物科技(苏州)有限公司 | 乐伐替尼-没食子酸共晶晶型及其应用 |
CN111689897B (zh) * | 2019-03-13 | 2024-02-06 | 齐鲁制药有限公司 | 一种高纯度甲磺酸乐伐替尼晶型c的制备方法 |
CN109867626A (zh) * | 2019-04-18 | 2019-06-11 | 安礼特(上海)医药科技有限公司 | 一种甲磺酸仑伐替尼多晶型物及其制备方法 |
CN111825609A (zh) * | 2019-04-22 | 2020-10-27 | 北京康辰药业股份有限公司 | 化合物晶型、其制备方法、药物组合物以及应用 |
CN110256341A (zh) * | 2019-06-27 | 2019-09-20 | 尚科生物医药(上海)有限公司 | 一种乐伐替尼甲磺酸盐晶型c的制备方法 |
CN110563644A (zh) * | 2019-10-30 | 2019-12-13 | 北京赛思源生物医药技术有限公司 | 一种仑伐替尼甲磺酸盐的新晶型 |
US11059787B2 (en) | 2019-11-12 | 2021-07-13 | Shenzhen Bolan Pharmaceutical Co., Ltd | Crystalline form of lenvatinib mesylate and methods thereof |
CN113135853A (zh) * | 2020-01-19 | 2021-07-20 | 重庆医药工业研究院有限责任公司 | 一种氟伐替尼或甲磺酸盐的晶型及其制备方法 |
CN111233762B (zh) * | 2020-02-20 | 2021-12-28 | 天津理工大学 | 一种乐伐替尼与对羟基苯甲酸共晶及其制备方法 |
CN111793027B (zh) * | 2020-08-07 | 2021-12-03 | 天津理工大学 | 一种乐伐替尼与苯甲酸的共晶及其制备方法 |
CN114213322B (zh) * | 2022-01-05 | 2023-11-07 | 中国药科大学 | 甲磺酸仑伐替尼没食子酸共晶及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1890220A (zh) * | 2003-12-25 | 2007-01-03 | 卫材株式会社 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法 |
CN101233111A (zh) * | 2005-06-23 | 2008-07-30 | 卫材R&D管理有限公司 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法 |
WO2016184436A1 (zh) * | 2015-05-21 | 2016-11-24 | 苏州晶云药物科技有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
-
2018
- 2018-04-20 WO PCT/CN2018/083861 patent/WO2018196687A1/zh active Application Filing
- 2018-04-20 CN CN201880024174.8A patent/CN110494423B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1890220A (zh) * | 2003-12-25 | 2007-01-03 | 卫材株式会社 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酰胺的盐或其溶剂合物的结晶及其制备方法 |
CN101233111A (zh) * | 2005-06-23 | 2008-07-30 | 卫材R&D管理有限公司 | 4-(3-氯-4-(环丙基氨基羰基)氨基苯氧基)-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法 |
WO2016184436A1 (zh) * | 2015-05-21 | 2016-11-24 | 苏州晶云药物科技有限公司 | 乐伐替尼甲磺酸盐的新晶型及其制备方法 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113533544A (zh) * | 2020-04-16 | 2021-10-22 | 先声药业有限公司 | 一种甲磺酸仑伐替尼的有关物质检测方法 |
CN114174264A (zh) * | 2020-04-24 | 2022-03-11 | 成都苑东生物制药股份有限公司 | 一种甲磺酸仑伐替尼晶型xi及其制备方法 |
CN114174264B (zh) * | 2020-04-24 | 2024-02-27 | 成都苑东生物制药股份有限公司 | 一种甲磺酸仑伐替尼晶型xi及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN110494423B (zh) | 2022-04-26 |
WO2018196687A1 (zh) | 2018-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110494423B (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
JP6542429B2 (ja) | N−(4−{[6,7−ビス(メチルオキシ)キノリン−4−イル]オキシ}フェニル)−n’−(4−フルオロフェニル)シクロプロパン−1,1−ジカルボキサミドのリンゴ酸塩およびその結晶質形態 | |
CN113527203B (zh) | 乐伐替尼甲磺酸盐的晶型及其制备方法和用途 | |
EP2753603B1 (en) | Polymorphic form of pridopidine hydrochloride | |
CN107428727B (zh) | 来那替尼马来酸盐的新晶型及其制备方法 | |
EP2454238A1 (en) | Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quinolin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide | |
EP3176173B1 (en) | Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof | |
CN114605406B (zh) | Amg510化合物的晶型及其制备方法和用途 | |
CN114773342A (zh) | Mrtx849化合物的晶型及其制备方法和用途 | |
US9884856B2 (en) | Crystal form of Dabrafenib mesylate and preparation method thereof | |
CN114920739A (zh) | Mrtx849化合物的晶型及其制备方法和用途 | |
JP6752822B2 (ja) | キナゾリンクロチル化合物二マレイン酸塩結晶、ならびに、その調製方法および使用 | |
CN114478374A (zh) | Toll样受体8特异性抑制剂盐酸盐及其制备方法和用途 | |
CN110903239A (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法 | |
WO2018138272A1 (en) | Eluxadoline crystalline form and process for the preparation thereof | |
WO2017215521A1 (zh) | Plx3397的盐酸盐晶型及其制备方法和用途 | |
CN108570045B (zh) | 氢溴酸山莨菪碱的晶型、其制备方法、药物组合物 | |
CN112125910A (zh) | 一种阿伐普替尼晶型及其制备方法 | |
US20150307484A1 (en) | Crystal Form of Dabrafenib and Preparation Method and Use Thereof | |
US10544129B2 (en) | Crystalline forms of AP26113, and preparation method thereof | |
CN106660965A (zh) | 乐伐替尼的对甲苯磺酸盐、其结晶形式及制备方法 | |
RU2684278C1 (ru) | Фумарат пиридиламина и его кристаллы | |
WO2023083293A1 (zh) | 依利格鲁司他可药用盐及其晶型 | |
CN111848677B (zh) | 一种alk激酶抑制剂化合物的晶型、制备方法及应用 | |
WO2023078424A1 (zh) | Kras突变体抑制剂的晶型、其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220426 |
|
CF01 | Termination of patent right due to non-payment of annual fee |